GB2563531A - Heterodimers and purification thereof - Google Patents

Heterodimers and purification thereof Download PDF

Info

Publication number
GB2563531A
GB2563531A GB1814284.4A GB201814284A GB2563531A GB 2563531 A GB2563531 A GB 2563531A GB 201814284 A GB201814284 A GB 201814284A GB 2563531 A GB2563531 A GB 2563531A
Authority
GB
United Kingdom
Prior art keywords
protein
heterodimers
purification
serine
human igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1814284.4A
Other versions
GB2563531B (en
GB201814284D0 (en
Inventor
C Jones Philip
Stadlmayr Gerhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Of Natural Resources And Life Sciences, University of
Original Assignee
Of Natural Resources And Life Sciences, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Of Natural Resources And Life Sciences, University of filed Critical Of Natural Resources And Life Sciences, University of
Publication of GB201814284D0 publication Critical patent/GB201814284D0/en
Publication of GB2563531A publication Critical patent/GB2563531A/en
Application granted granted Critical
Publication of GB2563531B publication Critical patent/GB2563531B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A protein comprising a human IgG Fc variant fragment monomer, capable of binding superantigen protein A, but not superantigen protein G [pA+/pG-] comprising serine at position (428), serine at position (434) and optionally histidine at position (436), with reference to human IgG1 or comprising these residues at the corresponding positions in human IgG 2, 3, or 4 as shown in the alignment in Figure 24, wherein positions are defined according to the EU index of Kabat.
GB1814284.4A 2016-02-05 2017-02-02 Heterodimers and purification thereof Active GB2563531B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1602156.0A GB201602156D0 (en) 2016-02-05 2016-02-05 Heterodimers and purification thereof
PCT/GB2017/050257 WO2017134440A2 (en) 2016-02-05 2017-02-02 Heterodimers and purification thereof

Publications (3)

Publication Number Publication Date
GB201814284D0 GB201814284D0 (en) 2018-10-17
GB2563531A true GB2563531A (en) 2018-12-19
GB2563531B GB2563531B (en) 2020-05-13

Family

ID=55641913

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1602156.0A Ceased GB201602156D0 (en) 2016-02-05 2016-02-05 Heterodimers and purification thereof
GB1814284.4A Active GB2563531B (en) 2016-02-05 2017-02-02 Heterodimers and purification thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1602156.0A Ceased GB201602156D0 (en) 2016-02-05 2016-02-05 Heterodimers and purification thereof

Country Status (2)

Country Link
GB (2) GB201602156D0 (en)
WO (1) WO2017134440A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058477A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN112218686A (en) 2018-04-11 2021-01-12 印希比股份有限公司 Multispecific polypeptide constructs with restricted CD3 binding and related methods and uses
TW202035451A (en) 2018-07-24 2020-10-01 美商英伊布里克斯公司 Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
MX2021001915A (en) * 2018-08-17 2021-05-31 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein.
TW202021986A (en) 2018-10-11 2020-06-16 美商英伊布里克斯公司 5t4 single domain antibodies and therapeutic compositions thereof
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
TW202028245A (en) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3 single domain antibodies and therapeutic compositions thereof
US12024556B2 (en) 2018-11-21 2024-07-02 Regeneron Pharmaceuticals, Inc. Anti-Staphylococcus antibodies and uses thereof
CN113966343A (en) 2019-06-11 2022-01-21 瑞泽恩制药公司 anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
KR20220024513A (en) * 2019-06-13 2022-03-03 리제너론 파아마슈티컬스, 인크. Methods for removing unwanted components during multi-stage chromatography processes
WO2021155071A1 (en) 2020-01-29 2021-08-05 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (en) * 2009-12-25 2011-06-30 中外製薬株式会社 Polypeptide modification method for purifying polypeptide multimers
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (en) * 2009-12-25 2011-06-30 中外製薬株式会社 Polypeptide modification method for purifying polypeptide multimers
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IRINA S. MOREIRA ET AL: 'Unraveling the Importance of Protein-Protein Interaction: Application of a Computational Alanine-Scanning Mutagenesis to the Study of the IgGl Streptococcal Protein G (C2 Fragment) Complex',THE JOURNAL OF PHYSICAL CHEMISTRY B, vol. 110, no. 22, 1 June 2006 *
JENDEBERG L ET AL: "Engineering of Fcl and Fc3 from human immunoglobulin G toanalyse subclass specificity for staphylococcal protein A", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL,vol. 201, no. l,14 February 1997 (1997-02-14), pages25-34, XP *
K N POTTER, YUCHENG LI, J DONALD CAPRA2F3, E, C DOMAINS, E: "Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950), AM ASSOC IMMNOL, UNITED STATES, 1 October 1996 (1996-10-01), UNITED STATES, pages 2982, XP055098543, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/8816406> *
SAUER-ERIKSSON, A.E. KLEYWEGT, G.J. UHLEN, M. JONES, T.A.: "Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG", STRUCTURE, ELSEVIER, AMSTERDAM, NL, vol. 3, no. 3, 1 March 1995 (1995-03-01), AMSTERDAM, NL, pages 265 - 278, XP004587842, ISSN: 0969-2126, DOI: 10.1016/S0969-2126(01)00157-5 *

Also Published As

Publication number Publication date
GB201602156D0 (en) 2016-03-23
GB2563531B (en) 2020-05-13
GB201814284D0 (en) 2018-10-17
WO2017134440A3 (en) 2017-10-19
WO2017134440A2 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
GB2563531A (en) Heterodimers and purification thereof
MX2019005426A (en) Anti-lag3 antibodies and antigen-binding fragments.
MX2018007406A (en) Anti-lag3 antibodies and antigen-binding fragments.
PH12016500291B1 (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2022002504A (en) Antibodies to cd40.
EP3390443A4 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2020013583A (en) Il-11 antibodies.
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
PH12020552229A1 (en) Il-11ra antibodies
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
MX2015011075A (en) Therapeutic peptides.
MX2015014017A (en) Fc region variant.
MX2017012662A (en) Polypeptides.
SG10201909716RA (en) Modified j-chain
MX2019007554A (en) Anti-neuropilin antigen-binding proteins and methods of use thereof.
SG11202007223SA (en) Fc binding proteins with cysteine in the c-terminal helical region
MX2018002164A (en) Anti-epha4 antibody.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2015016492A (en) Conotoxin peptides, pharmaceutical compositions and uses thereof.
EP3269735A4 (en) Anti-sclerostin antibody, antigen binding fragment and medical use thereof
MX2018001964A (en) Mrka polypeptides, antibodies, and uses thereof.
EP3773493A4 (en) Pedf-derived peptides for promoting meibomian gland regeneration and uses thereof
MX2017013014A (en) Antibody directed against immunoglobulin-binding proteins of s. aureus.
EP3883968A4 (en) Modified fc region

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20190103 AND 20190109